2Barchiesi F, Cogliati M, Esposto MC, et al. Comparative analysis of pathogenicity of Cryptoeoecus neoformans serotypes A, D and AD in murine cryptococcosis. J Infect,2005,51:10-16.
3Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: populationbased multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptoeoccal Active Surveillance Group. J Infect Dis, 1999,179:449-454.
4Currie BP, Casadevall A. Estimation of the prevalence of cryptececcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis, 1994,19:1029-1033.
5Mirza SA,Phelan M,Rimland D,et al. The changing epidemiology of cryptoeoecosis :an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis,2003,36:789-794.
6Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis, 1966,94:236-243.
7Saag MS,Graybill RJ,Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis ,2000,30:710-718.
5Jarvis J N, Harrison T S. Pulmonary cryptococosis [ J ]. Semin Respir Crit Care Med, 2008,29(2) :141.
6Kerkering T M, Duma R J, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors[ J-. Ann Intern Med, 1981,94(5) :611-616.
7Wong-Beringer A, Jacobs R A, Gugllelmo B J. Lipid for- mulations of amphotericin B: clinical efficacy and toxici- ties[Jl. Clin Infect Dis, 1998,27(3) :603-618.
8Chang W C, Tzao C, Hsu H H, et al. Pulmonary crypto- coccosis: comparison of clinical and radiographic charac- teristics in immunecompetent and immunecompromised patients [ J ]. Chest, 2006,129 ( 2 ) : 333 -340.
9Bateman E D, Hurd S S, Barnes P J, et al. Global strat- egy for asthma management and prevention: GINA execu- tive summary[J]. Eur Respir J, 2008,31 ( 1 ) :143-178.
10Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: pharmacologic characteris- tics, clinical efficacy, and tolerability [ J ]. Transpl Infect Dis, 1999,1 (4) :273-283.
